Aiforia achieves CE-IVD mark for clinical PD-L1 AI model in lung cancer diagnostics
Aiforia announces the CE-IVD mark of its Aiforia® Clinical AI Model for Lung Cancer; PD-L1 for assisting pathologists in the fast and accurate primary diagnosis of lung cancer. This latest AI model expands Aiforia’s portfolio of clinical diagnostics solutions for pathology.Worldwide the most common cause of cancer mortality in 2020 was lung cancer, with an estimated 1.80 million deaths occurring¹. Fortunately, immunotherapies are increasing in prominence and efficacy². A popular target for these novel therapeutics is PD-L1, a vital biomarker indicating cancer progression³. The calculation